Followers | 10 |
Posts | 1578 |
Boards Moderated | 0 |
Alias Born | 10/15/2014 |
Tuesday, July 11, 2017 11:14:46 AM
How we got here:
1. Too much hype (by Braeburn) on the probuphine launch..."the most successful implant launch in history..." etc. Braeburn's flawed launch...doctors trained but did not prescribe. No sales force until January 2017. Insurance pre-authorization rules making just getting the medicine extremely difficult. The entire rehab/counseling industry speaking out against implants that might adversely affect their revenue stream.
2. The low float allowed shorts to entirely manage the price post-approval. Dumping by Broadfin and Braeburn didn't help.
3. Being included on the index funds was a double edged sword. We didn't get any bump up from buying (funds buy over time to control price movement), but we sure were punished getting kicked off (dumping in June).
4. Management has fumbled, bumbled and stumbled. Delayed Parkinson's trial. No EU deal. Spending precious resources on pre-clinical work for the DOD on a malaria implant that does not seem likely to be commercially viable unless the US goes to war in a jungle environment.
5. I couldn't recommend TTNP to a friend right now, because I'm not sure how they are going to fund next year. It seems dilution is likely, and so why not wait to see how much dilution there is before buying in.
How could management get out of this mess (without just selling the company):
1. Outlicense parkinsons now to GlaxoSmithKline. For GSK, it would essentially allow them to control implant sales for the product they once had the patent on. And it would be cheap for them: although technically pre-IND, this drug is 3 trials away from approval. Get some upfront license cash to take care of 2018. It would also lend some more credibility to the Pro Neura technology.
2. Sign the damn EU license deal. There may or may not be upfront cash, but add some certainty that ex-US development is actually happening.
3. Focus on hypo-thyroidism. That market dwarfs addiction treatment or parkinsons. This is the Pro Neura application that Titan wants to own as an approved drug without a partnership.
4. Stop spending time and money on non-essential development programs. Malaria, autism, etc. are great for the Gates Foundation, but this is a for profit enterprise (despite what management might believe).
5. Communicate honestly and transparently with stockholders. Take all questions on conference calls...it really irks me that this company is owned 80% by street holders, but they will only speak with analysts on conference calls. Fair enough if 80% were owned by institutions, but the stock price lives or dies by the individual investor right now, so stop treating them with contempt.
Recent TTNP News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:33:11 PM
- Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria • GlobeNewswire Inc. • 01/25/2024 09:29:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:59:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:13:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:20 PM
- Titan Pharmaceuticals Announces Reverse Stock Split and Ratio • GlobeNewswire Inc. • 12/28/2023 09:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:47:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:03:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:33:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:31:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:29:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:25:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:23:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/24/2023 09:26:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/23/2023 07:07:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:08:35 PM
- Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors • GlobeNewswire Inc. • 10/16/2023 08:37:23 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/04/2023 09:30:18 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/19/2023 08:41:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 08:45:22 PM
- Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock • GlobeNewswire Inc. • 09/18/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 09:30:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2023 08:28:25 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM